

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Myeloproliferative disorder	Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1; GLUT1)	<i>In vitro</i> and mouse studies suggest inhibiting GLUT1 could help prevent weight loss associated with myeloproliferative disorder. In a mouse model of myeloproliferative disorder, adipose tissue atrophy, glucose consumption by leukocytes and inflammation in bone marrow were greater than what was seen in control mice. In three mouse models of the disease, small hairpin RNA-mediated knockdown of Glut1 in the bone marrow decreased adipose tissue loss compared with no knockdown. Next steps could include identifying and testing GLUT1 inhibitors in animal models.	Patent and licensing status unavailable	Gautier, E.L. <i>et al. J. Exp. Med.</i> ; published online Jan. 14, 2013; doi:10.1084/jem.20121357 Contact: Laurent Yvan-Charvet, Columbia University, New York, N.Y. e-mail: ly2159@columbia.edu
<p><i>SciBX</i> 6(5); doi:10.1038/scibx.2013.115 Published online Feb. 7, 2013</p>				